Today, Galderma Group AG announced its sales performance for the first quarter of 2025. The company reported net sales of $1.129 billion, representing year-on-year growth of 8.3% on a constant currency basis, setting a new first-quarter record.
Galderma attributed this performance to volume-driven growth, supported by a favorable product mix and strong execution across markets. The company noted particular momentum in Injectable Aesthetics and the successful ramp-up of Nemluvio, its recently launched treatment for atopic dermatitis and prurigo nodularis.
Growth was broad-based across all product categories and geographies. International markets continued to show strong double-digit growth, led by key countries such as Canada, China, Germany, India, and the U.K.. In the United States, the company returned to growth, supported by the strong uptake of Nemluvio, solid performance in Dermatological Skincare, and a rebound in Injectable Aesthetics.
The Dermatological Skincare segment achieved net sales of $370 million, reflecting 7.8% year-on-year growth on a constant currency basis. This was driven by strong performances from both Cetaphil® and Alastin®, particularly in International markets. Galderma continued to launch new innovations in this segment, including Cetaphil SPF40 Tinted Face Lotion and Alastin’s TriHex+™ Skin Complex in the U.S. In its digital-first and retailer-focused execution, Galderma is making significant strides with its efforts to rebrand Cetaphil to Gen Zs, including through major advocacy campaigns featuring prominent healthcare professionals and skinfluencers.
Commenting on the results, Flemming Ørnskov, M.D., MPH, Chief Executive Officer of Galderma, said:“Galderma is off to an outstanding start in 2025. Our broad-based performance across product categories and geographies perfectly illustrates the strength of our Integrated Dermatology Strategy. With the successful launch of two major innovations—Nemluvio and Relfydess—and continued commercial excellence, we remain firmly on track to deliver on our full-year outlook.”
